Last updated: 11/17/2026 12:11:40

Comparison of Renal Outcomes of Belimumab versus Immunosuppressants (IS) in Participants With Systemic Lupus Erythematosus (SLE)

GSK study ID
308726
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Planned
Planned
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Comparative Analysis of Renal Outcomes in a Real-World Population with Systemic Lupus Erythematosus (SLE) Treated with Belimumab or Immunosuppressants (IS)
Trial description: This study aims to compare renal outcomes associated with initiation of belimumab versus standard of care (SOC) immunosuppressants (IS) among participants with systemic lupus erythematosus (SLE) in routine clinical practice. Index date will be defined as the earliest date of initiation of belimumab or an SOC IS after 01 January 2017. The 12-month period before index date will be defined as the baseline period.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Time to Composite Outcome (TTCO) of Renal Flare (Moderate or Severe) or Progression to Lupus Nephritis (LN)

Timeframe: Up to approximately 9.25 years from index date

Secondary outcomes:

Time to Progression to LN (TTLN)

Timeframe: Up to approximately 9.25 years from index date

Time to First Moderate or Severe Renal Flare

Timeframe: Up to approximately 9.25 years from index date

TTCO and TTLN Among Participants With and Without Baseline Organ Damage

Timeframe: Up to approximately 9.25 years from index date

TTCO and TTLN Among Participants With Mild SLE Disease and Participants With Moderate or Severe SLE Disease During the 6 Months Before Index Date

Timeframe: Up to approximately 9.25 years from index date

TTCO and TTLN Among Participants With Government-sponsored Insurance and Participants With Commercial Insurance at Index Date

Timeframe: Up to approximately 9.25 years from index date

TTCO and TTLN Among Participants With at least 12 Months of Continuous Enrollment After Index Date

Timeframe: Up to approximately 9.25 years from index date

Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
2026-31-12
Observational study model:
Cohort
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Systemic Lupus Erythematosus
Product
GSK1550188-belimumab
Collaborators
Not applicable
Study date(s)
November 2026 to December 2026
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Initiation of treatments of interest on or after 01 January 2017 (date of initiation defined as the index date):
  • o For belimumab cohort: greater than or equal to (>=) 1 claim for treatment with belimumab OR
  • >= 1 claim for diagnosis of drug-induced lupus, any time before the index date
  • >= 1 indicator of LN, any time before the index date, defined as:

Trial location(s)

No location data available.

Study documents

No study documents available.

Results overview

No study documents available

Recruitment status
Planned
Actual primary completion date
Not applicable
Actual study completion date
Not applicable

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website